The main ongoing studies: REDEFINE 1 , Phase 3 obesity without T2D (results 20242025, preliminarily 25.3 %) REDEFINE 2 , Phase 3 obesity + T2D REDEFINE 3 , Phase 3 cardiovascular outcome trial (n~7000) Stand-alone clinical development of Cagrilintide is limited , Novo Nordisk is primarily investing in the CagriSema combination
Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials
00:04:18 Vickie Danaher So if you read the studies, you may notice that the approved dosages and dosage forms of orforglipron are different than what was used in the clinical trials
Abstract Purpose of Review Obesity pharmacotherapy is rapidly evolving with the ability of glucagon-like peptide- 1 receptor agonists (GLP-1RAs) to improve atherosclerotic cardiovascular disease (ASCVD) outcomes
The pressure to breastfeed
We dont think of bad air as a gut issue, but it is